Key Points
- Treasurer Edmund Fay sold 11,937 shares on March 9 at an average price of $107 for a total of $1,277,259, reducing his ownership by 11.79% to 89,325 shares; the sale was disclosed in an SEC filing.
- Encompass Health beat expectations with $1.46 EPS vs. $1.29 consensus and reported $3.09B in revenue, and the company set FY‑2026 guidance of $5.81–$6.10 EPS while analysts maintain a consensus target of $143.29 and mostly Buy ratings.
- The company declared a quarterly dividend of $0.19 (annualized $0.76) for a yield of about 0.7%, with an ex‑dividend date of April 1 and payment on April 15.
Encompass Health Corporation (NYSE:EHC - Get Free Report) Treasurer Edmund Fay sold 11,937 shares of the firm's stock in a transaction on Monday, March 9th. The stock was sold at an average price of $107.00, for a total value of $1,277,259.00. Following the completion of the sale, the treasurer directly owned 89,325 shares of the company's stock, valued at $9,557,775. This trade represents a 11.79% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Encompass Health Trading Down 1.7%
Shares of EHC stock opened at $106.75 on Wednesday. Encompass Health Corporation has a twelve month low of $92.53 and a twelve month high of $127.99. The stock has a market cap of $10.61 billion, a price-to-earnings ratio of 19.27, a PEG ratio of 2.08 and a beta of 0.71. The company's 50-day moving average price is $103.92 and its 200-day moving average price is $113.37. The company has a current ratio of 1.08, a quick ratio of 1.08 and a debt-to-equity ratio of 0.76.
Encompass Health (NYSE:EHC - Get Free Report) last issued its earnings results on Thursday, February 5th. The company reported $1.46 EPS for the quarter, topping analysts' consensus estimates of $1.29 by $0.17. Encompass Health had a net margin of 9.54% and a return on equity of 18.20%. The company had revenue of $3.09 billion for the quarter, compared to the consensus estimate of $1.54 billion. During the same period in the previous year, the firm earned $1.17 earnings per share. Encompass Health's quarterly revenue was up 9.9% compared to the same quarter last year. Encompass Health has set its FY 2026 guidance at 5.810-6.100 EPS. As a group, equities analysts predict that Encompass Health Corporation will post 4.8 earnings per share for the current year.
Encompass Health Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 15th. Stockholders of record on Wednesday, April 1st will be paid a $0.19 dividend. This represents a $0.76 annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend is Wednesday, April 1st. Encompass Health's dividend payout ratio is 13.72%.
Institutional Trading of Encompass Health
Several hedge funds have recently made changes to their positions in EHC. Royal Bank of Canada increased its position in shares of Encompass Health by 21.5% during the first quarter. Royal Bank of Canada now owns 88,470 shares of the company's stock worth $8,960,000 after purchasing an additional 15,677 shares in the last quarter. Millennium Management LLC increased its holdings in shares of Encompass Health by 38.4% in the 1st quarter. Millennium Management LLC now owns 92,197 shares of the company's stock valued at $9,338,000 after acquiring an additional 25,574 shares during the period. Caxton Associates LLP purchased a new stake in Encompass Health in the 1st quarter valued at $259,000. Savant Capital LLC grew its position in Encompass Health by 7.4% during the 2nd quarter. Savant Capital LLC now owns 3,121 shares of the company's stock worth $383,000 after purchasing an additional 214 shares during the last quarter. Finally, Parkside Financial Bank & Trust increased its stake in Encompass Health by 179.5% in the second quarter. Parkside Financial Bank & Trust now owns 478 shares of the company's stock valued at $59,000 after purchasing an additional 307 shares during the period. Institutional investors and hedge funds own 97.25% of the company's stock.
Wall Street Analysts Forecast Growth
Several analysts recently issued reports on EHC shares. Zacks Research lowered shares of Encompass Health from a "strong-buy" rating to a "hold" rating in a report on Wednesday, November 19th. Wall Street Zen raised shares of Encompass Health from a "hold" rating to a "buy" rating in a research note on Sunday, January 18th. Finally, Barclays boosted their price target on shares of Encompass Health from $150.00 to $153.00 and gave the company an "overweight" rating in a research note on Friday, February 6th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $143.29.
View Our Latest Report on EHC
Encompass Health Company Profile
(
Get Free Report)
Encompass Health Corporation is a leading provider of post‐acute healthcare services in the United States, operating a comprehensive network of inpatient rehabilitation hospitals and home health and hospice agencies. Its inpatient rehabilitation hospitals offer intensive therapy programs for patients recovering from conditions such as stroke, brain injury, spinal cord injury, cardiac and pulmonary disorders, and orthopedic procedures. Through its home health segment, Encompass Health delivers skilled nursing, physical therapy, occupational therapy and speech therapy to patients in the comfort of their homes, while its hospice services provide end‐of‐life care focused on symptom management and emotional support for patients and families.
Founded in 1984 as HealthSouth Corporation and rebranded as Encompass Health in 2018, the company has grown organically and through acquisitions to serve patients across more than 30 states.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
